AXSOME THERAPEUTICS INC

Axsome Therapeutics surges: analyst‑backed $290 target, 40% upside forecast, and a decade of growth—discover the pipeline, risks, and investor insights.

Explore Axsome Therapeutics’ rise to $233.8 Nasdaq, its focus on pain & neurological drugs, and why its growth fuels biopharma innovation.

Axsome Therapeutics Inc has delivered a strong financial performance, exceeding expectations and signaling a robust future for the biopharmaceutical company despite facing significant challenges.

Axsome Therapeutics exceeded Q2 2025 expectations, reporting a 72% year-over-year revenue growth and surpassing earnings forecasts.

Axsome Therapeutics reported a loss in Q1 2025, but exceeded revenue expectations with a 62% top-line growth, driven by its CNS portfolio expansion, and its stock performance remains resilient despite financial losses.

Axsome Therapeutics reported a 60% increase in Q1 revenue, beating expectations, despite a net loss, and is awaiting a potential FDA approval for its fibromyalgia treatment, AXS-14, in Q2 2025.

Axsome Therapeutics Inc. reported a 60% revenue growth in Q1 2025, exceeding expectations despite a reported loss, and is poised for future success with its strategic CNS portfolio expansion.